Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kadcyla + atezolizumab vs Kadcyla + placebo in HER2+/PD-L1+ LABC/MBC
CTR20211008Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine, atezolizumab in breast cancer, sponsored by Roche. Started May 2021; status: terminated.
02
Drugs
trastuzumab emtansineatezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211008.